All-oral 12-week Combination Treatment With Daclatasvir (DCV) and Sofosbuvir (SOF) in Patients Infected with HCV Genotype (GT) 3: ALLY-3 Phase 3 Study

被引：0

作者：

Nelson, David R. ^{[1
]}

Cooper, James N. ^{[2
]}

Lalezari, Jacob P. ^{[3
]}

Lawitz, Eric ^{[4
]}

Pockros, Paul J. ^{[5
]}

Gitlin, Norman ^{[6
]}

Freilich, Bradley ^{[7
]}

Younes, Ziad ^{[8
]}

Harlan, William ^{[9
]}

Ghalib, Reem H. ^{[10
]}

Oguchi, Godson I. ^{[11
]}

Thuluvath, Paul J. ^{[12
]}

Ortiz-Lasanta, Grisell ^{[13
]}

Rabinovitz, Mordechai ^{[14
]}

Bernstein, David ^{[15
]}

Bennett, Michael ^{[16
]}

Hawkins, Trevor ^{[17
]}

Ravendhran, Natarajan ^{[18
]}

Sheikh, Aasim M. ^{[19
]}

Varunok, Peter ^{[20
]}

Kowdley, Kris V. ^{[21
]}

Hennicken, Delphine ^{[22
]}

McPhee, Fiona ^{[22
]}

Rana, Khurram ^{[22
]}

Hughes, Eric A. ^{[22
]}

机构：

[1] Univ Florida, Gainesville, FL USA

[2] Inova Fairfax Hosp, Falls Church, VA USA

[3] Quest Clin Res, San Francisco, CA USA

[4] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA

[5] Scripps Clin, La Jolla, CA 92037 USA

[6] Atlanta Gastroenterol Associates, Atlanta, GA USA

[7] Kansas City Res Inst, Kansas City, MO USA

[8] Gastro One, Germantown, TN USA

[9] Asheville Gastroenterol Associates, Asheville, NC USA

[10] Texas Clin Res Inst, Arlington, TX USA

[11] Midland Florida Clin Res Ctr, Deland, FL USA

[12] Mercy Med Ctr, Baltimore, MD USA

[13] Fdn Invest Diego, Santurce, PR USA

[14] Univ Pittsburgh, Pittsburgh, PA USA

[15] Hofstra North Shore Long Isl Jewish Sch Med, Manhasset, NY USA

[16] Med Associates Res Grp, San Diego, CA USA

[17] Southwest CARE Ctr, Santa Fe, NM USA

[18] Digest Dis Associates, Baltimore, MD USA

[19] Gastrointestinal Specialists Georgia, Marietta, GA USA

[20] Premier Med Grp Husdon Valley, Poughkeepsie, NY USA

[21] Swedish Med Ctr, Seattle, WA USA

[22] Bristol Myers Squibb Res & Dev, Princeton, NJ USA

来源：

HEPATOLOGY | 2014年 / 60卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

LB-3

引用

页码：1268A / 1269A

页数：2

共 50 条

[31] All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study
Jacobson, Ira M.
Marcellin, Patrick
Mangia, Alessandra
Kwo, Paul Y.
Foster, Graham
Buti, Maria
Brau, Norbert
Muir, Andrew J.
Yang, Jenny C.
Mo, Hongmei
Ding, Xiao
Pang, Phil
Symonds, William T.
McHutchison, John G.
Zeuzem, Stefan
Afdhal, Nezam H.
GASTROENTEROLOGY, 2014, 146 (05) : S903 - S903
[32] ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY
Mangia, A.
Marcellin, P.
Kwo, P.
Foster, G. R.
Buti, M.
Braeu, N.
Muir, A.
Yang, J. C.
Mo, H.
Ding, X.
Pang, P. S.
Symonds, W. T.
McHutchison, J. G.
Zeuzem, S.
Afdhal, N.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S523 - S524
[33] Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
Leroy, Vincent
Angus, Peter
Bronowicki, Jean-Pierre
Dore, Gregory J.
Hezode, Christophe
Pianko, Stephen
Pol, Stanislas
Stuart, Katherine
Tse, Edmund
McPhee, Fiona
Bhore, Rafia
Jimenez-Exposito, Maria Jesus
Thompson, Alexander J.
HEPATOLOGY, 2016, 63 (05) : 1430 - 1441
[34] ALL-ORAL THERAPY WITH DACLATASVIR IN COMBINATION WITH ASUNAPREVIR AND BMS-791325 FOR TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE 4 INFECTION
Hassanein, T.
Sims, K.
Bennett, M.
Gitlin, N.
Lawitz, E.
Nguyen, T.
Webster, L.
Younossi, Z.
Schwartz, H.
Thuluvath, P. J.
Zhou, H.
Rege, B.
McPhee, F.
Zhou, N.
Wind-Rotolo, M.
Chung, E.
Griffies, A.
Grasela, D.
Gardiner, D. F.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S472 - S472
[35] All-Oral Therapy With Daclatasvir in Combination With Asunaprevir and Bms-791325 for Treatment-Naive Patients With Chronic HCV Genotype 4 Infection
Hassanein, Tarek
Everson, Gregory T.
Sims, Karen
Bennett, Michael T.
Gitlin, Norman
Lawitz, Eric
Nguyen, Tuan T.
Webster, Lynn R.
Younossi, Zobair M.
Schwartz, Howard I.
Thuluvath, Paul J.
Zhou, Helen
Rege, Bhaskar
McPhee, Fiona
Wind-Rotolo, Megan
Chung, Ellen
Griffies, Amber M.
Grasela, Dennis M.
Gardiner, David F.
GASTROENTEROLOGY, 2014, 146 (05) : S926 - S926
[36] Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naive Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China
Xu, Xiaoyuan
Feng, Bo
Guan, Yujuan
Zheng, Sujun
Sheng, Jifang
Yang, Xingxiang
Ma, Yuanji
Huang, Yan
Kang, Yi
Wen, Xiaofeng
Li, Jun
Tan, Youwen
He, Qing
Xie, Qing
Wang, Maorong
Anl, Ping
Gong, Guozhong
Liu, Huimin
Nine, Qin
Hua, Rui
Ning, Bo
Xie, Wen
Zhang, Jiming
Huang, Wenxiang
Yang, Yongfeng
Lin, Minghua
Zhao, Yingren
Yu, Yanhong
Jia, Jidong
Yang, Dongliang
Chen, Liang
Ye, Yinong
Nan, Yuemin
Gong, Zuojiong
Zhang, Quan
Hu, Peng
Wang, Fusheng
Li, Yongguo
Li, Dongliang
Jia, Zhansheng
Hou, Jinlin
Chen, Chengwei
Wu, Jinzi J.
Wei, Lai
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2019, 7 (03) : 213 - 220
[37] LOW SUSTAINED VIROLOGIC RESPONSE (SVR) RATES IN GENOTYPE (GT) 2 AND 3 PATIENTS WITH QUANTIFIABLE HEPATITIS C VIRUS (HCV) AT WEEK 4 OF TREATMENT WITH SOFOSBUVIR (SOF) CONTAINING REGIMENS
Thornton, K.
Deming, P.
Sedillo, M.
Qualls, C.
Box, T.
Scott, J.
Cox, P.
Mera, J.
Miller, A.
Manch, R.
Kohli, A.
Gish, R.
Moore, A.
Sussman, N.
Khaderi, S.
Arora, S.
JOURNAL OF HEPATOLOGY, 2016, 64 : S786 - S786
[38] All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Manns, Michael
Pol, Stanislas
Jacobson, Ira M.
Marcellin, Patrick
Gordon, Stuart C.
Peng, Cheng-Yuan
Chang, Ting-Tsung
Everson, Gregory T.
Heo, Jeong
Gerken, Guido
Yoffe, Boris
Towner, William J.
Bourliere, Marc
Metivier, Sophie
Chu, Chi-Jen
Sievert, William
Bronowicki, Jean-Pierre
Thabut, Dominique
Lee, Youn-Jae
Kao, Jia-Horng
McPhee, Fiona
Kopit, Justin
Mendez, Patricia
Linaberry, Misti
Hughes, Eric
Noviello, Stephanie
LANCET, 2014, 384 (9954): : 1597 - 1605
[39] High Rate of Sustained Virologic Response with the All-Oral Combination of Daclatasvir (NS5A Inhibitor) Plus Sofosbuvir (Nucleotide NS5B Inhibitor), With or Without Ribavirin, in Treatment-Naive Patients Chronically Infected With HCV Genotype 1, 2, or 3
Sulkowski, Mark S.
Gardiner, David F.
Rodriguez-Torres, Maribel
Reddy, K. Rajender
Hassanein, Tarek
Jacobson, Ira M.
Lawitz, Eric
Lok, Anna S.
Hinestrosa, Federico
Thuluvath, Paul J.
Schwartz, Howard
Nelson, David R.
Eley, Timothy
Wind-Rotolo, Megan
Huang, Shu-Pang
Gao, Min
McPhee, Fiona
Sherman, Diane
Hindes, Robert
Symonds, William T.
Pasquinelli, Claudio
Grasela, Dennis M.
HEPATOLOGY, 2012, 56 (06) : 1516 - 1517
[40] SVR12 results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease
Lawitz, Eric
Poordad, Fred
Gutierrez, Julio A.
Kakuda, Thomas
Picchio, Gaston
Beets, Greet
Vandevoorde, Ann
Van Remoortere, Peter
Jacquemyn, Bert
Quinn, Gemma
Luo, Donghan
Ouwerkerk-Mahadevan, Sivi
Vijgen, Leen
Van Eygen, Veerle
Beumont, Maria
HEPATOLOGY, 2015, 62 : 227A - 227A

← 1 2 3 4 5 →